Myasthenia Gravis is an adult neuromuscular disorder that affects approximately 5 in 100,000 people.
It is due to a dysfunction of the immune system: the autoimmune reaction is directed against constituents of the neuromuscular junction, the interface between the nerve and the muscle, which results in a defect of transmission of the nerve impulse. This is manifested by fatigability and a lack of muscle strength.
Clinical trials ongoing at the Institute:
- UCB MG0007 : A Phase 3, open-label extension (OLE) study to evaluate 6-week treatment cycles of rozanolixizumab in study participants with gMG
- ALX1720: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel, Multicenter Study to Evaluate the Safety and Efficacy of ALXN1720 in Adults with Generalized Myasthenia Gravis
- R3918-MG-2018 : Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients with Symptomatic Generalized Myasthenia Gravis
- MOM-M281-011 : Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Nipocalimab Administered to Adults with Generalized Myasthenia Gravis
- ARGX-113-2003 – ADAPT NXT: A Phase 3b, Randomized, Open-label, Parallel-Group Study to Evaluate Different Dosing Regimens of Intravenous Efgartigimod to Maximize and Maintain Clinical Benefit in Patients With Generalized Myasthenia Gravis
- MYAPATH: Creation of a collection of biological resources for the study of pathologies that can lead to Myasthenia Gravis
Acronym |
UCB MG0007 |
ALX1720 |
| Intervention | rozanolixizumab | ALXN1720 |
| Principal investigator |
Sophie Demeret | Sophie Demeret |
| Sponsor | UCB | Alexion |
| Study status | Ongoing | Ongoing |
| Recruitment status | Completed | Not started |
| Population | Adult | Adult |
| + infos on clinicaltrials.gov | + infos on clinicaltrials.gov |
Acronym |
R3918-MG-2018 |
MOM-M281-011 |
ARGX-113-2003 – ADAPT NXT |
MYAPATH |
| Intervention | pozelimab et cemdisiran | nipocalimab | Efgartigimod | – |
| Principal investigator | Sophie Demeret | Sophie Demeret | Sophie Demeret | Anthony Béhin |
| Sponsor | Regeneron | Jannsen-Cilag | Argenx | AIM |
| Study status | In preparation | Ongoing | Ongoing | Ongoing |
| Recruitment status | Not started | Ongoing | Ongoing | Ongoing |
| Population | Adult | Adult | Adult | Adult |
| + infos on clinicaltrials.gov | + infos on clinicaltrials.gov | + infos on clinicaltrials.gov |
Contact : essais-adultes@institut-myologie.org
